BACKGROUND: Neuraxial clonidine is used for perioperative analgesia in children of all ages. Preclinical studies in the postnatal rat allow comparison of the relative toxicity and safety of spinal analgesics throughout postnatal development. METHODS: Rat pups aged 3, 7, or 21 postnatal (P) days were briefly anesthetized for intrathecal injections of saline or clonidine. At each age, the maximum tolerated, antinociceptive (increased hindlimb mechanical withdrawal threshold) and antihyperalgesic (hindpaw carrageenan inflammation) doses were determined. Lumbar spinal cord sections were assessed for apoptosis and cell death (histology, activated caspase-3 immunohistochemistry, Fluoro-Jade C staining), histopathology (hematoxylin and eosin staining), and increased glial reactivity (microglial and astrocytic markers). P3 intrathecal ketamine sections served as positive controls. In additional groups, thermal latency and mechanical withdrawal threshold were measured at P35. RESULTS: Intrathecal clonidine produces age-and dose-dependent analgesia in rat pups. Maximal doses of clonidine did not alter the degree or distribution of apoptosis or increase glial reactivity in the neonatal spinal cord. No spinal histopathology was seen 1 or 7 days after injection at any age. Intrathecal clonidine did not produce persistent changes in reflex sensitivity to mechanical or thermal stimuli at P35. CONCLUSIONS: Intrathecal clonidine in the postnatal rat did not produce signs of spinal cord toxicity, even at doses much larger than required for analgesia. The therapeutic ratio (maximum tolerated dose/antihyperalgesic dose) was Ͼ300 at P3, Ͼ30 at P7, and Ͼ10 at P21. These data provide additional information to inform the clinical choice of spinal analgesic drug in early life.
P reclinical work demonstrated that spinal delivery of clonidine produced potent analgesia 1,2 through an effect on spinal ␣ 2 -adrenergic receptors. 3 Subsequent human studies with neuraxial clonidine demonstrated clinical efficacy in adults 4 for the management of acute postoperative, 5,6 labor, 7, 8 and postcesarean 9 pain, as well as for longer-term management of chronic neuropathic 10, 11 and cancer pain. 12 In pediatric practice, spinal clonidine has been used primarily for perioperative pain management, either as an additive to prolong analgesia with single-shot caudal local anesthetic [13] [14] [15] or to improve analgesia and reduce local anesthetic requirements in epidural infusions. 16, 17 Although the majority of controlled trials have been conducted in infants and children, neuraxial clonidine has also been used in neonates, via either the caudal 18 -20 or intrathecal (IT) route. 21, 22 Laboratory studies have confirmed that spinal ␣ 2 agonist analgesic mechanisms are functional from early development, and IT clonidine 23 and epidural dexmedetomidine 24, 25 have both antihyperalgesic and antinociceptive effects in rat pups from the third postnatal (P3) day. Epidural dexmedetomidine produces spinally mediated dose-dependent analgesic effects at all postnatal ages, but the sensitivity to sedative 24 and cardiovascular 25 side effects is also increased in early life.
The benefits of spinal analgesia must always be balanced by the potential risk of neurotoxicity when drugs are administered in relatively high concentrations close to the spinal cord, and adequate preclinical testing before routine clinical use has been advocated. 26 -28 In adult animals, repeated injections or continuous infusions of spinally administered clonidine for 14 days or longer have not produced neurotoxic effects in rats 29, 30 or dogs, 31, 32 and bolus doses did not reduce spinal cord blood flow in sheep 33 or pigs. 34 Responses to analgesics and anesthetics may differ in the developing nervous system. 35 In particular, anesthetics with ␥-amino butyric acid agonist or N-methyl-d-aspartate antagonist action increase neuronal apoptosis or cell death in the primate 36 -39 and rodent brain. 40 -42 Accordingly, it is important when evaluating novel neuraxial therapeutics for neonates and infants to define the potential effects of the drug with respect to the developing spinal cord. We have recently developed a model for assessing spinal toxicity in the neonatal rat that includes evaluation of (i) dosedependent analgesic effects; (ii) histopathology, neuronal apoptosis, and glial reactivity in the spinal cord at doses up to the maximum tolerated; and (iii) functional outcomes. 43, 44 Calculation of a therapeutic ratio (toxic dose/ analgesic dose) allows comparison of the effects of different drugs at different postnatal ages. In this model, morphine had a high therapeutic ratio, i.e., toxicity was not seen at 300 times the analgesic dose in neonatal rats. 44 In contrast, IT ketamine increased apoptosis and glial reactivity in the spinal cord and produced persistent changes in gait and mechanical threshold in the same dose range as analgesia; i.e., its therapeutic ratio was Ͻ1. 43 Because clonidine is a potential alternative to ketamine for caudal analgesia in pediatric patients, 15 we have now evaluated the analgesic effects and potential for spinal apoptosis and toxicity after single-dose IT clonidine in the postnatal rat.
METHODS

Experimental Animals
The study protocol and experiments were performed with personal and project licenses approved by the United Kingdom Home Office, in a laboratory approved for regulated procedures, and in accordance with the requirements for the care of laboratory animals of the United Kingdom Animal (Scientific Procedures) Act 1986. Sprague-Dawley dams and litters were bred in-house in the Biological Services Unit University College London, and were maintained on a 12-hour light/dark cycle at constant ambient temperature with free access to food and water. Postnatal (P) day 3, 7, or 21 male and female rat pups, with mean body weights of 10, 16, and 54 g, respectively, were assigned to treatment groups. Within each litter, pups were randomly selected, numbered, and assigned to treatment groups. Data from animals within the same litter were treated as independent values, and treatment groups and group comparisons comprised animals from Ͼ1 litter. Overall, 12 litters from each age group were used. An independent colleague coded drug solutions to ensure the experimenter was unaware of treatment allocation during testing. The degree of handling and duration of maternal separation were minimized, and were the same for saline control and clonidine treatment animals. Litters were restricted to a maximum of 12, and pups were weaned into same-sex cages at P21.
Behavioral Testing
In P3, P7, and P21 rats, mechanical withdrawal thresholds were measured with handheld von Frey hairs (vFh) that apply a logarithmically increasing force (vFh 5 ϭ 0.13 g to vFh 13 ϭ 7.8 g). 45 Testing was performed on the dorsal hindpaw because it is difficult to maintain body temperature or reliably apply mechanical stimuli to the plantar surface through an elevated mesh platform in small pups. Rats were lightly restrained on a flat bench surface and vFh were applied 5 times at 1-second intervals to the dorsal surface of the hindpaw, as previously described. 24, 43, 45, 46 The number of evoked flexion reflexes to increasingintensity stimuli was recorded, until a given stimulus evoked 5 withdrawal responses or a suprathreshold cutoff pressure was reached (7.8 g at P3, 13 g at P7, or 60 g at P21).
To evaluate any persistent changes in sensory function after IT injection at P3, P7, or P21, sensory thresholds were measured at 5 weeks of age (P35). After habituation on an elevated mesh platform, the mechanical stimulus (electronic von Frey device; Dynamic Plantar Aesthesiometer, Ugo Basile, Collegeville, PA) was applied to the midplantar surface of the hindpaw. The mechanical threshold was averaged from 3 measures of the force (0 -50 g; ramp 20 g/s) required to produce hindlimb withdrawal. Thermal withdrawal latency was determined using a modified Hargreaves Box (University Anesthesia Research and Development Group, University of California San Diego, La Jolla, CA), 47 consisting of a glass surface (maintained at 30°C) on which the rats were placed in individual Plexiglas cubicles. The thermal nociceptive stimulus from a focused projection bulb positioned below the glass surface was directed to the midplantar hindpaw. Latency was defined as the time required for the paw to show a brisk withdrawal as detected by photodiode motion sensors that stopped the timer and terminated the stimulus. In the absence of a response within 20 seconds, the stimulus was terminated (cutoff time). Thermal latency was the average of 3 measures from each hindpaw.
IT Injection Technique
Pups were anesthetized with halothane (3%-5%) in oxygen and air. Percutaneous IT injections were made at the low lumbar level (intervertebral space L4-5 or L5-6) with a 30-gauge needle perpendicular to the skin, connected to a microinjector and 50-L Hamilton syringe. Based on our previous work, 44 an injectate volume of 0.5 L per gram body weight was used because this provides a uniform spread across lumbar and low thoracic segments in rat pups of all current age (and corresponding weight) groups. After preparation of different concentrations of clonidine, an independent colleague coded samples of drug and saline to ensure that the experimenter (SMW) was unaware of treatment group during behavioral testing.
IT Clonidine Dose
Determination of Maximum Tolerated Dose
In pilot experiments, IT clonidine hydrochloride (Sigma-Aldrich, St. Louis, MO) dissolved in sterile saline was administered to P3, P7, and P21 pups in escalating doses of 0.1, 0.3, 1, 3, 10, and 30 mg/kg. Dose escalation was limited by behavioral disturbance and weight loss, rather than by acute cardiovascular collapse or sedation and respiratory depression. Doses resulting in marked behavioral disturbance (reduced activity and freezing, alternating with agitation or excitation) were also associated with failure of normal daily weight gain or actual weight loss. Behavioral and motor changes were more apparent in the older pups, and occurred at lower doses. After doses of 3 mg/kg clonidine and larger in P21 pups, piloerection, urinary voiding, and shivering with significant hypothermia (temperature Ͻ31°C) were also observed. As a result, temperature was monitored at intervals in all pups by holding a surface electrode between the upper limb and thorax in the "axilla" of P3 pups or inserting a rectal probe in P10 or P21 pups. A warming protocol (thermostatically controlled heating blanket within open topped Perspex container) was established to ensure that body temperature was maintained after injection of saline or clonidine in subsequent experimental groups. The maximum tolerated dose of IT clonidine was defined as the dose that did not produce weight loss in individual animals (when comparing values preinjection and 24 hours postinjection of clonidine) or significant group differences from saline controls. This provided a quantifiable outcome that could be standardized across the postnatal ages. In subsequent experimental groups, the maximum tolerated dose at each age produced mild acute behavioral changes, but body temperature and body weight were maintained.
For clarity, IT doses are expressed as milligram/ kilogram. However, because the concentration of drug is important for the direct effect upon local tissues after IT delivery, the range of concentrations and mean total dose for each treatment group are also presented in Table 1 .
Evaluation of Antinociceptive Doses
IT clonidine doses up to the maximum tolerated were administered to evaluate acute antinociceptive effects. Individual pups received single doses of saline or clonidine. Mechanical withdrawal threshold was determined at baseline, correct IT placement was confirmed by a significant increase in threshold 30 minutes after injection, and thresholds were again measured before death and spinal cord harvesting at 24 hours or 7 days after injection. Single injections of the maximum tolerated dose were administered for tissue analysis, 44 because our model aimed to deliver the highest possible concentration of drug to evaluate local tissue toxicity. Also, repeated administration is not feasible because IT catheters can produce confounding injuries in small pups. 23 To confirm that effects at these doses were not solely due to systemic absorption, mechanical thresholds 30 minutes after subcutaneous administration of clonidine in the midlumbar region (10 mg/kg at P3 or 3 mg/kg at P7 and P21 in 5 L/g; n ϭ 6 per group) were also evaluated.
In separate groups of animals, the maximum tolerated dose of IT clonidine was administered to P3 (10 mg/kg), P7 (3 mg/kg), or P21 (1 mg/kg) pups (n ϭ 8 per group). Control animals received IT saline (n ϭ 6 -8 per group). Mechanical withdrawal thresholds were measured at baseline and 30 minutes after injection to confirm IT placement. Animals were maintained and regularly reviewed in the UCL Biological Services Unit, weaned into same-sex cages at P21, and weight, mechanical withdrawal threshold, and thermal withdrawal latency were measured at 5 weeks of age.
Evaluation of Antihyperalgesic Doses
Hindpaw inflammation was induced in P3, P7, and P21 pups by injection of 1 L/g of 2% carrageenan (Sigma-Aldrich) into the midplantar surface of the left hindpaw under brief halothane (2%-4%) in oxygen anesthesia. 24 Mechanical withdrawal thresholds were measured at baseline and 3 hours after carrageenan injection to quantify the degree of hyperalgesia. IT saline or clonidine (0.03-0.3 mg/kg; n ϭ 5-6 all groups) was administered as described above. Mechanical withdrawal thresholds were measured 15 and 30 minutes after injection, with the investigator (SMW) unaware of the treatment allocation.
Spinal Cord Preparation, Staining, and Analysis
Spinal cord tissue was analyzed 24 hours and 7 days after injection as previously described 43, 44 (n ϭ 4 per treatment group). In brief, animals were killed with 100 mg/kg intraperitoneal pentobarbitone, and then transcardially perfused with heparinized saline followed by 4% paraformaldehyde. Spinal cords were dissected, postfixed in 4% paraformaldehyde, and then cryoprotected in 30% sucrose. Using a cryostat, 7-and 14-m sections of lower lumbar spinal cord were taken and mounted on Fisher Superfrost Plus slides (Fisher Scientific, Houston, TX) and stored at Ϫ70°C.
For each analysis, sections were coded and the investigator was unaware of the treatment group. For quantitative analyses, at least 4 nonconsecutive sections of lumbosacral cord from each animal were examined and the mean was determined. Different sections were used for caspase-3 immunohistochemistry, Fluoro-Jade C staining, or hematoxylin and eosin (H&E) staining at 24 hours, and for H&E staining and glial immunoreactivity at 7 days. Sections from P3 pups that had received 10 mg/kg IT preservativefree ketamine hydrochloride (Sigma-Aldrich) as previously described 43 were stained in parallel to act as a positive control for the staining protocol and to ensure that the sample size was sufficient to detect treatment effects previously associated with both structural and functional changes. 43 All statistical analyses were calculated with n representing the number of animals within each treatment group. 
Fluoro-Jade C Staining
Fluoro-Jade C (FJ-C; Millipore, Temecula, CA) staining was performed as previously described 48 
Statistical Analysis
For evaluation of mechanical withdrawal threshold in pups, the number of withdrawal responses was plotted against the mechanical stimulus (force expressed as grams on log 10 scale). A sigmoidal stimulus-response curve with nonvariable slope was constructed using nonlinear regression curve fit. The midpoint of the curve (50% effective force; EF 50 ) was determined and designated the threshold. 24, 46 In adults, mechanical withdrawal thresholds and thermal latencies were the mean of 3 values for each hindpaw. The degree of reversal of inflammatory hyperalgesia for each animal was calculated from the mechanical withdrawal thresholds at different time points: (30 minutes after clonidine Ϫ inflamed)/(baseline Ϫ inflamed) ϫ 100. Treatment groups were compared with 1-way analysis of variance (ANOVA) followed by Bonferroni post hoc test for multiple comparisons or Dunnett multiple comparison, or Student t test if comparison was limited to 2 groups. P35 sensory threshold values were tested for normality (D'Agostino and Pearson normality test) and also assessed by 2-way ANOVA with treatment (saline or different clonidine doses) and sex (male or female) as variables.
Data were analyzed using Prism Version 5.0 (GraphPad, San Diego, CA). P Ͻ 0.05 was considered statistically significant.
RESULTS
IT Clonidine Produces Dose-Dependent Analgesic Effects at All Postnatal Ages
Effects of Clonidine on Mechanical Withdrawal Threshold
The maximum tolerated IT clonidine dose was 10 mg/kg at P3 and 3 mg/kg at P7. These doses produced mild behavioral effects initially that did not preclude sensory testing at 30 minutes, and body weight was maintained at 24 hours and 7 days. In P21 pups, 3 mg/kg clonidine produced more marked behavioral effects (reduced movement but initial excitatory responses on handling), but minimal weight loss at 24 hours (56.7 Ϯ 1.1 g at baseline vs 54.7 Ϯ 1.8 g), and this dose was used for acute evaluations. However, because body weight was lower than saline controls by 3 days after injection, the lower dose of 1 mg/kg was designated the maximum tolerated dose in P21 pups for evaluation at 7 days after injection and at P35. Mechanical withdrawal thresholds increase with postnatal age, from a mean of 1.3 g at P3, 1.6 g at P7 to 11.9 g at P21 ( Table 2) . IT clonidine produced dose-dependent antinociceptive effects at all postnatal ages. Thirty minutes after IT injection, mechanical withdrawal thresholds did not differ from baseline in the saline control groups, but were significantly increased by 1 mg/kg clonidine at all postnatal ages (P Ͻ 0.05 or P Ͻ 0.01; 1-way ANOVA with Dunnett comparison with baseline; Fig. 1 ). Systemic administration of the highest clonidine dose also increased mechanical withdrawal threshold compared with baseline, but effects were significantly less than when the same dose was administered IT at P3 (10 mg/kg subcutaneous [s.c.] vs IT ϭ 1.3 Ϯ 0.08 g vs 3.0 Ϯ 0.14 g; P Ͻ 0.01), at P7 (3 mg/kg s.c. vs IT ϭ 2.8 Ϯ 0.19 g vs 3.8 Ϯ 0.25 g; P Ͻ 0.05), or at P21 (3 mg/kg s.c. vs IT ϭ 30 Ϯ 3 g vs 74 Ϯ 6 g; P Ͻ 0.01, 1-way ANOVA with Bonferroni post hoc comparisons).
Inflammatory Hyperalgesia
Three hours after hindpaw injection of carrageenan, mechanical withdrawal thresholds in the inflamed paw were significantly decreased at all postnatal ages ( Fig. 2A ; P Ͻ 0.001, paired 2-way Student t test). The minimum dose of IT clonidine that produced a significant reversal of inflammatory hyperalgesia was 0.03 mg/kg at P3 and 0.1 mg/kg at P7 (P Ͻ 0.01), and 0.3 mg/kg at P21 (P Ͻ 0.05, 1-way ANOVA with Dunnett comparison with saline; Fig. 2B ). Consistent with previous data after epidural dexmedetomidine, 24 antihyperalgesic effects of IT clonidine were seen at lower doses than antinociceptive effects at all ages. In addition, age-dependent analgesic effects were evident after inflammation, with lower dose requirements in the younger pups.
IT Clonidine Does Not Produce Persistent Changes in Sensory Thresholds
After IT injection of clonidine 10 mg/kg at P3, 3 mg/kg at P7, or 1 mg/kg at P21, mechanical withdrawal thresholds ( Table 2 ) and body weight ( Table 3 ) did not differ from saline control groups 24 hours or 7 days after injection. In additional animals, more persistent effects on spinal reflex sensitivity were assessed at P35. There were no significant differences in mechanical withdrawal threshold or thermal withdrawal latency after IT injection of clonidine or saline at P3, P7, or P21 (Table 2 ; not significant, 1-way ANOVA with Bonferroni multiple post hoc comparisons). There was no main effect of treatment (F 3,36 ϭ 0.43, P ϭ 0.73) or sex (F 1,36 ϭ 0.71, P ϭ 0.55) on mechanical withdrawal threshold at P35. Similarly, there was no main effect of treatment (F 3,36 ϭ 0.23, P ϭ 0.87) or sex (F 1,36 ϭ 0.43, P ϭ 0.43) on thermal withdrawal latency at P35. Treatment accounted for 5.3% and 4%, and sex for Ͻ0.1% and 1.6% of total variance in mechanical threshold and thermal latency, respectively (2-way ANOVA with treatment and gender as variables).
Maximal Tolerated Doses of IT Clonidine Do Not Increase Apoptosis or Produce Histopathological Changes in Rat Pups
The number of Fluoro-Jade C-positive neurons 24 hours after saline injection decreased with age (P4: 11.1 Ϯ 1.02; P8: 6.5 Ϯ 1.2; P22: 2.5 Ϯ 0.5; P Ͻ 0.01, 1-way ANOVA linear trend) and the majority were found in the dorsal horn (Fig.  3, A and B) . IT clonidine had no effect on the number or distribution of Fluoro-Jade C-positive cells at any age. By contrast, IT ketamine 10 mg/kg at P3 significantly increased the number of Fluoro-Jade C-positive cells in the lumbar spinal cord, with the largest increase in the dorsal horn (Fig. 3A) . Similarly, maximum tolerated doses of IT clonidine at P3 or P7 did not increase apoptotic cell counts as identified by activated caspase-3 immunohistochemistry (Fig. 4) . Significant increases were seen in the P3 ketamine 10 mg/kg positive control group.
Spinal cord sections stained with H&E were evaluated for histopathological changes after IT injection. The agerelated decrease in apoptosis is again demonstrated in data from animals 24 hours after injection (P4, P8, P22) and 7 days after injection (P10, P14, P28). Within each age group, the number of apoptotic profiles after any dose of IT clonidine did not differ from the saline control group (Fig.  5) . None of the spinal cords showed histopathological changes such as necrosis, inflammation, or microglial nodules.
IT Clonidine Does Not Increase Glial Reactivity in the Neonatal Spinal Cord
Glial reactivity 7 days after IT injection was assessed by immunohistochemistry for microglial (Iba1; Fig. 6, A and B ) and astrocytic (GFAP; Fig. 6C ) markers. The mean density of Iba1 or GFAP immunofluorescence in the dorsal horn was not altered by maximum doses of IT clonidine at P3, P7, or P21. However, significant increases were seen in the P3 ketamine group (Fig. 6 ).
Postnatal Age and Therapeutic Ratio of IT Clonidine
Based on the above results, the therapeutic ratio calculated as the quotient of the maximum tolerated dose and the minimum dose that significantly increased mechanical threshold in the uninjured paw was calculated as Ͼ10 at P3 (10/1) and Ͼ3 at P7 and P21 (3/1). Using the antihyperalgesic dose as the measure of analgesic activity, the therapeutic ratio at P3 was Ͼ300 (10/0.03), at P7 was Ͼ30 (3/0.1), and at P21 was Ͼ10 for acute apoptosis (3/0.3) and Ͼ3 for persistent sensory effects (1/0.3). Because the maximum dose was limited by systemic side effects and there were no signs of local spinal toxicity, the ratio for spinal effects is designated as greater than the given ratio rather than an absolute value.
DISCUSSION
These are the first systematic studies evaluating the potential spinal toxicity of IT clonidine in a neonatal model. IT clonidine dose-dependently reverses inflammatory hyperalgesia at all postnatal ages, and higher doses increase sensory thresholds in uninjured paws (i.e., have antinociceptive effects). Single, maximum tolerated doses/ concentrations of IT clonidine did not produce signs of local tissue toxicity at any postnatal age as measured by several criteria. First, IT clonidine did not increase apoptotic cell counts identified by activated caspase-3 immunohistochemistry or histological examination, or alter the number or distribution of Fluoro-Jade C-positive neurons 24 hours after injection. IT clonidine did not produce histopathological changes in the spinal cord or alter markers of microglial or astrocytic reactivity. Finally, IT clonidine had no persistent effects on spinal cord reflex sensitivity to mechanical or thermal stimuli at P35. The absence of effects of clonidine were similar to those after morphine, 44 but in contrast to the effects after IT ketamine in P3 animals as reported previously 43 and confirmed in parallel sections in the current study. Clonidine is an ␣-adrenergic agonist with an approximate 160-fold selectivity for the ␣ 2 versus ␣ 1 receptor. 49 Early preclinical work pointed to the potent spinal action of ␣ 2 agonists such as clonidine in regulating the processing of nociceptive information after both tissue and nerve injury in adult animals. 1, 2, 50 Spinal ␣ 2 agonists have age-and dose-dependent analgesic effects throughout postnatal development. [23] [24] [25] The current study confirms reversal of hyperalgesia by IT clonidine, with lower dose requirements in the youngest pups. Higher IT doses are antinociceptive, and although maximum tolerated IT doses produce additional systemic side effects, analgesic effects are still more marked than when the same dose is administered systemically.
Safety evaluation of spinal clonidine has been undertaken in adult dogs after repeated bolus 32 or extended continuous epidural 31 and IT 51 delivery. No evidence of spinal pathology was observed. Similarly, IT administration for 14 days did not result in toxicity in the adult rat. 29, 30 These findings are based on histological evaluation performed by a neuropathologist, and similar methodology here has also failed to demonstrate histopathology in the cord of neonatal and young rats after single-dose IT clonidine. Of particular interest, clonidine has been reported to have antiinflammatory actions, [52] [53] [54] [55] and coadministration reduces the local inflammatory effects evoked by chronic low-dose IT morphine in the canine model. 51 Alpha 2 agonists may also have specific advantages in combination therapy in early development. Systemic dexmedetomidine reduced general anesthetic-related apoptosis in P7 rats, although efficacy varied in different brain regions, 56, 57 and effects in the spinal cord have not been evaluated. The effect of combinations of different IT analgesics and local anesthetics throughout postnatal development warrants future evaluation.
Given the concern regarding general anesthesia in neonates and increased interest in neuraxial anesthesia, 58 we have emphasized the need to develop a safety database to define the potential toxicity of drugs for spinal delivery at different developmental ages. 59 The present work with clonidine, and previous work with morphine, 44 ketamine, 43 and bupivacaine 60 are the only systematic preclinical spinal safety data in postnatal rats. Several points should be emphasized. Assessment of developmental safety must recognize that there are age-dependent changes in connectivity in the developing spinal cord, 35, 61 and treatments that alter afferent traffic, such as N-methyl-d-aspartate antagonists 43 and general anesthetics 60, 62 can increase apoptosis in the spinal cord, and persistently modify spinal cord structure and function. 43, 63, 64 Accordingly, as in our previous studies, 43, 44 we specifically examined treatment effects at P3, P7, and P21, a developmental time span that extends from the critical neonatal period through to childhood in humans. Consistent with our current and previous reports, spontaneous apoptosis in the spinal cord of postnatal rats occurs largely in the dorsal horn from P2 to P5, decreasing by P8 to 10. 65, 66 The brief anesthesia used for our IT injection protocol has no additional impact, because the number of apoptotic cells did not differ between naïve and IT saline animals. 44 Here, maximum tolerated doses of clonidine did not alter the number or distribution of apoptotic cell profiles as assessed by histological examination, activated caspase-3 immunohistochemistry, or Fluoro-Jade C staining. In addition, there was no evidence of a delayed injury response because there was no histopathological change or increase in glial reactivity 7 days after injection. After general anesthetic exposures that increase cortical and hippocampal apoptosis in rodents, changes in higher cognitive functions such as learning and memory have been reported at intervals from 4 weeks to 8 months. 67 We evaluated sensory thresholds at P35, when both sensory 61 and motor 68, 69 components of reflex function are fully mature, and descending modulation from the rostroventral medulla has reached adult patterns by P25. 70 Whereas IT ketamine at P3 increased apoptosis and altered mechanical withdrawal thresholds and gait, 43 single, maximal doses of IT clonidine did not alter reflex sensitivity at P35.
Clonidine has an established role as a spinal adjuvant analgesic in pediatric practice, and clonidine via the IT 71 or caudal/epidural 72 route has a greater effect than the same dose IV. Epidural clonidine 0.08 to 0.12 g/kg/h produces dose-dependent analgesia when added to local anesthetic infusions, 17 and higher doses of clonidine alone (0.2 g/kg/h preceded by bolus of 2 g/kg) provide analgesia at rest after abdominal surgery. 73 Clonidine 1 to 2 g/kg prolongs analgesia when added to caudal local anesthetic, with cardiovascular and sedative side effects at doses of 5 g/kg in children, 15 but sensitivity to side effects (apnea, oxygen desaturation, and bradycardia) is greater in neonates. 18 -20 Similarly, when added to IT local anesthetic, clonidine prolonged analgesia in neonates, 21 but an increased proportion were sedated and developed selflimiting apnea postoperatively. 22 Caudal dexmedetomidine has analgesic properties 74 similar to clonidine 75 in infants and children, but there has been limited preclinical evaluation of toxicity. 59, 76 The merits of different spinal analgesics have been discussed in several clinical reviews, but concerns about the relative safety of different drugs and preparations have also been expressed. 15, [77] [78] [79] Current practice differs across centers and countries because the availability of preparations varies and there are limited clinical data relating to comparative efficacy or long-term outcomes. 16, 80 Within-study comparisons of caudal clonidine and ketamine have variably reported more prolonged analgesia with ketamine 81, 82 or no difference. 83 Addition of clonidine to ketamine further prolonged analgesia in one study, 84 but provided no benefit in another. 85 Between 2002 and 2009, the proportion of pediatric anesthesiologists adding clonidine to caudal local anesthetic in the United Kingdom increased, and use of caudal ketamine remained relatively stable. 13, 14 However, decreased use of ketamine in Europe 86 has been attributed to guidelines reporting laboratory toxicity with preservative-free ketamine in adult animals. 87 Our previous study 43 and the direct comparisons used here suggest that ketamine has specific developmental effects that reduce the safety margin for spinal administration in early development.
One of the conundrums facing the interpretation of preclinical safety data is the translation of dosing from the animal model to the human condition. We have suggested that one useful strategy is to compare the therapeutic ratio (i.e., the minimum spinal dose at which toxicity is observed divided by the maximally therapeutic dose), because this would provide a conservative estimate for comparison of different drugs. The definition of the therapeutic dose clearly depends on the end point selected. In previous work, we evaluated antinociceptive effects of morphine to a mechanical stimulus. 44 Because ketamine has minimal effects on baseline thresholds, we evaluated antihyperalgesic effects after hindpaw inflammation. 43 Here we evaluated both antinociceptive and antihyperalgesic effects of clonidine, and as shown previously in rat pups after epidural morphine 88, 89 or epidural dexmedetomidine, 24 lower doses of IT clonidine were required to reverse inflammatory hyperalgesia than to produce antinociceptive effects. Analgesic dose requirements for morphine, ketamine, and clonidine were age-dependent and lowest at P3. Because analgesic requirements vary with the type of drug and with age (e.g., carrageenan-induced hyperalgesia was reversed by clonidine 30 g/kg and ketamine 3 mg/kg at P3, and by clonidine 300 g/kg and ketamine 15 mg/kg at P21), equianalgesic effects rather than absolute doses are used to calculate the relative therapeutic ratio. Using antihyperalgesic doses, therapeutic ratios for IT clonidine were Ͼ300 at P3, Ͼ30 at P7, and Ͼ10 at P21. Similarly, maximal doses of morphine did not produce toxicity, and the therapeutic ratio was high. 44 By contrast, IT ketamine increased apoptosis in the same dose range as analgesia, and the calculated therapeutic ratio did not exceed 1. 43 This approach has potential weaknesses. From the perspective of the spinal drug, the principal variable defining local tissue effects are the local concentration of the drug in the spinal canal and the duration of that exposure. 26 Because repeated dosing via IT catheters is not practical in small pups, single doses were given and the maximum testable dose of clonidine, morphine, and ketamine was limited by systemic side effects. Although systemic side effects are of concern, our principal focus for toxicity is the local effect on spinal tissues. In the event that the maximum tolerable dose after IT delivery is not associated with toxicity, we can only conclude that the therapeutic ratio is at least, or more than, a certain value. This value will be low if systemic side effects preclude assessment of higher doses/concentrations. Conversely, if local spinal toxicity occurs at a dose lower than the therapeutic analgesic effect, one can assert that the therapeutic ratio is Յ1. We would argue that, despite these limitations on achieving absolute values, this methodology allows us to compare the relative safety margin of different drugs at given stages of development. A relatively wide safety margin has been demonstrated with morphine 44 and now with clonidine. The comparisons with ketamine presented here and previously 43 confirm that spinal clonidine has a wider safety margin than spinal ketamine in the neonatal rat. These data provide additional information to inform the clinical choice of spinal analgesic in early life.
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